DrugMonitor™ Anti-Canakinumab Antibody (VS-1224-YC249) (CAT#: VS-1224-YC249)
Canakinumab is a recombinant anti-human IL-1β monoclonal antibody marketed for treating Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). The DrugMonitor™ Anti-Canakinumab Antibody (VS-1224-YC249) is an anti-drug antibody (ADA) against Canakinumab. This drug-based antibody is raised in mice immunized with the Canakinumab. The anti-Canakinumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Canakinumab in samples.
Specific Inquiry
Specifications
- Host Animal
- Mouse
- Specificity
- Canakinumab
- Target
- Canakinumab
- Immunogen
- Canakinumab
- Type
- Mouse IgG
- Species Reactivity
- Human
- Purity
- >95%
- Purification
- Protein G
- Applications
- ELISA, PK/PD, ADA control
- Format
- Liquid
- Concentration
- Batch-dependent
- Buffer
- PBS, pH 7.4
- Preservative
- No preservatives
- Storage
- Store at 4°C for 1-2 weeks and at -20°C for 1 year. Avoid repeated freezing and thawing.
- Generic name
- Canakinumab
- Drug Weight
- 145157.0 Da (deglycosylated)
- Formula
- C₆₄₅₂H₉₉₅₈N₁₇₂₂O₂₀₁₀S₄₂
- Related Disease
- Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS)
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Canakinumab"
Anti-Human IL1Beta Recombinant Antibody (Canakinumab)Recombinant monoclonal antibody to Human IL1 beta. Canakinumab is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.
Canakinumab was for the treatment of rheumatoid arthritis. Canakinumab is as a possible treatment for chronic obstructive pulmonary disease, gout and coronary artery disease.
Afuco™ Anti-IL1B ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-021)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human IL1 beta. It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.
Customer Reviews and Q&As
There are currently no Customer reviews or questions for VS-1224-YC249. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: FuncS, IF, Neut, ELISA, FC, IP, ICC
Application: ELISA, Neut, IF, IP, FC, FuncS
Application: ELISA, IP, FC, FuncS, Neut, IF, IHC
Application: Neut, ELISA, IF, IP, FuncS, FC, IHC
Application: IF, IP, Neut, FuncS, ELISA, FC, WB
Application: WB, ELISA, FuncS
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: ELISA, IHC, FC, IP, IF, Inhib
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
